Cantor Fitzgerald Keeps Overweight on NBIX Neurocrine Biosciences March 2026

On March 10, 2026 Cantor Fitzgerald kept NBIX at Overweight and raised its price target to $195. The NBIX analyst rating update signals continued confidence in Ingrezza revenue prospects. We focus on the rating, the new $195 target, and what this means for investors and trading risk.

NBIX analyst rating from Cantor Fitzgerald

Cantor Fitzgerald issued the action on March 10, 2026 and maintained Overweight on NBIX. The firm also raised its price target to $195, per the StreetInsider note. The published note tracked a minimal intraday change of 0.11% ($0.14) on the update.

What the maintained Overweight means for investors

Maintaining Overweight signals that Cantor Fitzgerald sees NBIX outperforming peers. Investors should view this as a positive stance, not a guarantee of immediate gains. The rating suggests confidence in Neurocrine Biosciences’ product outlook, especially Ingrezza sales trends. It supports a buy-tilted posture for risk-tolerant investors.

NBIX price target implications and market context

A $195 price target provides an explicit valuation anchor from Cantor Fitzgerald. Comparing that target to current trading levels helps estimate upside, but investors must calculate their own entry points. The company’s market cap stands at $13,033,139,180, giving scale to the PT and indicating the analyst view applies to a large-cap biotech stock.

Historical analyst coverage and rating trends for Neurocrine Biosciences, Inc.

Neurocrine Biosciences has drawn sustained analyst coverage over years due to its commercial product Ingrezza and pipeline. Cantor Fitzgerald’s continued Overweight is consistent with recent positive commentary from specialty biotech analysts. Investors should track multiple firms, as consensus shifts often follow new sales data or trial news.

Trading impact and risk considerations

Short-term stock moves often lag analyst notes. The small immediate price change of 0.11% ($0.14) shows limited intraday reaction to this note. Investors must weigh clinical, regulatory, and competitive risks. Ratings and PTs guide conviction but do not eliminate volatility.

How to follow NBIX analyst rating updates

We track updates in real time and reference the original analyst note on StreetInsider. For this change see StreetInsider. For broader rating context see recent aggregator coverage on Investing.com. Track the stock on Meyka with our NBIX page for live analyst updates: NBIX on Meyka.

Final Thoughts

Cantor Fitzgerald’s March 10, 2026 note maintained an Overweight stance on NBIX and raised the price target to $195. The NBIX analyst rating confirms confidence in Neurocrine Biosciences’ Ingrezza outlook and signals a buy-leaning position for investors who accept biotech risk. The update produced a modest immediate market move of 0.11% ($0.14), showing limited short-term reaction. Meyka AI rates NBIX with a grade of A. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Use the Cantor Fitzgerald view together with other analyst notes and company fundamentals before making investment decisions. Meyka AI provides real-time coverage and tools to follow NBIX analyst rating changes and price target shifts.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.